LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Search

Quidel Corp

Fechado

10.99 -12.78

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.14

Máximo

12.6

Indicadores-chave

By Trading Economics

Rendimento

602M

-131M

Vendas

24M

724M

Margem de lucro

-18.062

Funcionários

6,500

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+66.43% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-509M

700M

Abertura anterior

23.77

Fecho anterior

10.99

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de mai. de 2026, 23:41 UTC

Ganhos

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 de mai. de 2026, 21:40 UTC

Ganhos

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 de mai. de 2026, 23:13 UTC

Ganhos

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 de mai. de 2026, 23:13 UTC

Ganhos

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 de mai. de 2026, 23:12 UTC

Ganhos

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 de mai. de 2026, 23:11 UTC

Ganhos

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 de mai. de 2026, 23:07 UTC

Ganhos

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 de mai. de 2026, 23:06 UTC

Ganhos

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 de mai. de 2026, 23:06 UTC

Ganhos

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 de mai. de 2026, 23:05 UTC

Ganhos

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 de mai. de 2026, 23:04 UTC

Ganhos

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 de mai. de 2026, 22:50 UTC

Ganhos

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 de mai. de 2026, 22:25 UTC

Conversa de Mercado

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 de mai. de 2026, 22:11 UTC

Ganhos

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 de mai. de 2026, 22:11 UTC

Ganhos

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 de mai. de 2026, 22:05 UTC

Conversa de Mercado

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 de mai. de 2026, 21:58 UTC

Ganhos

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 de mai. de 2026, 21:47 UTC

Conversa de Mercado
Ganhos

Costco Posts 13% Sales Growth in April -- Market Talk

6 de mai. de 2026, 21:46 UTC

Ganhos

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 de mai. de 2026, 21:40 UTC

Ganhos

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 de mai. de 2026, 21:35 UTC

Conversa de Mercado

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 de mai. de 2026, 21:32 UTC

Ações em Alta

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 de mai. de 2026, 21:29 UTC

Ganhos

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

66.43% parte superior

Previsão para 12 meses

Média 20.67 USD  66.43%

Máximo 30 USD

Mínimo 15 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

1

Comprar

3

Manter

1

Vender

Informação Financeira

Custos administrativos e de venda

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

Resultado Operacional

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat